

LE GINECO A L'ASCO 2023 !

CLINICAL SCIENCE SYMPOSIUM – SURGICAL MANAGEMENT OF GYNECOLOGICAL CANCERS (Vendredi 2 juin à 14h45 – E451)

SHAPE / GCIG

Abstract #LBA5511

GYNECOLOGICAL CANCER ORAL SESSION (Samedi 3 juin à 15h – Hall D1)

COLIBRI / GINECO – CE108b

Abstract #5501

DUO-O / ENGOT-ov46

Abstract #LBA5506

LATE BREAKING GYNECOLOGICAL ORAL SESSION (Dimanche 4 juin à 7h30 – Hall D1)

MIRASOL / ENGOT-ov55

Abstract #LBA5507

GYNECOLOGICAL CANCER POSTER DISCUSSION (Lundi 5 juin à 16h30 – S100bc)

RAMP201 / ENGOT-ov60

Abstract #5515

NIQOLE / GINECO-ov239b

Abstract #5521

METASTATIC BREAST CANCER ORAL SESSION (Lundi 5 juin à 11h30 – Hall B1)

PADA-1 / UGBG-GINECO

Abstract #1002

CLINICAL SCIENCE SYMPOSIUM – ORAL SESSION

SHAPE

Marie Plante – Abstract LBA #5511

An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CTG CX.5-SHAPE).

GYNECOLOGICAL CANCER ORAL SESSION

**COLIBRI /
GINECO – CE108b****Isabelle Ray-Coquard – Abstract #5501**

In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study.

**DUO-O /
ENGOT-ov46****Philipp Harter – Abstract LBA#5506**

Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.

**MIRASOL /
ENGOT-ov55****Kathleen N. Moore – Abstract LBA#5507**

Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.

GYNECOLOGICAL CANCER POSTER DISCUSSION

**RAMP201 /
ENGOT-ov60-****Susana N. Banerjee - Abstract #5515**

Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).

**NIQOLE/
GINECO-ov239b****Florence Joly – Abstract #5521**

Toxicity profile and discordance between patients/physicians regarding niraparib maintenance in recurrent ovarian cancer (ROC) patients: Lessons from the NIQOLE real-life study—GINECO study.

METASTATIC BREAST CANCER ORAL SESSION

PADA-1

Francois Clement Bidard – Abstract #1002

Dynamics and type of ESR1 mutations under aromatase inhibitor or fulvestrant combined with palbociclib after randomization in the PADA-1 trial.